Can naltrexone benefit co‑occurring psychiatric conditions such as depressive disorder, anxiety disorder, post‑traumatic stress disorder, or borderline personality disorder?

Naltrexone for Co-Occurring Psychiatric Conditions

Naltrexone shows limited but emerging evidence for benefit in specific co-occurring psychiatric conditions, particularly borderline personality disorder and PTSD with alcohol use disorder, but is not FDA-approved or guideline-recommended as a primary treatment for depression, anxiety, PTSD, or BPD as standalone conditions.

Current FDA-Approved Indications

Naltrexone is FDA-approved exclusively for:

• Alcohol use disorder (maintaining abstinence) 1
• Opioid use disorder (preventing relapse) 1

Critically, FDA clinical trials for naltrexone specifically excluded patients with psychosis, dementia, and secondary psychiatric diagnoses 1, meaning safety and efficacy data in primary psychiatric populations are limited.

Evidence by Psychiatric Condition

Borderline Personality Disorder (BPD)

The strongest evidence for off-label psychiatric use exists for BPD, particularly for self-injurious behavior and dissociative symptoms.

• A retrospective analysis of 161 BPD inpatients found naltrexone was the only medication significantly associated with treatment response (OR 43.2, p ≤ 0.0001), with dose-dependent effects: higher doses (OR 791.8) outperformed lower doses (OR 26.6), though even low doses exceeded other pharmacological treatments 2

• Naltrexone at 2-6 mg/day (low-dose) improved dissociative symptoms in 11 of 15 patients with trauma-related disorders, with 7 reporting lasting benefit. Patients described clearer perception, improved reality assessment, and better self-regulation 3

• The mechanism involves blocking opioid receptors that modulate dissociative phenomena 4, 3

Important caveat: Reducing dissociation may expose patients to overwhelming distress if they lack adequate coping mechanisms, as dissociation previously served a protective function 3

Post-Traumatic Stress Disorder (PTSD)

Evidence supports naltrexone only when PTSD co-occurs with alcohol use disorder, not as monotherapy for PTSD.

• In 93 patients with comorbid PTSD and alcohol dependence, those receiving active medication (naltrexone, disulfiram, or combination) had better alcohol outcomes than placebo, with overall PTSD symptoms improving 5

• This suggests naltrexone's benefit in PTSD may be indirect—through reducing alcohol use rather than directly treating PTSD symptoms 5

Depression

The evidence is mixed and contradictory regarding depression:

• Naltrexone-bupropion combination (FDA-approved for obesity) showed improvement in depressive symptoms in a small open-label study of women with major depressive disorder at 24 weeks 6. The bupropion component (300 mg daily) is itself an FDA-approved antidepressant 6

• However, naltrexone monotherapy did not worsen depression in opioid-dependent patients; adherent patients actually showed fewer depressive symptoms than non-adherent ones 7

• In alcohol-exposed mice, naltrexone reversed anxiety- and depressive-like behaviors and reduced neuroinflammation 8

• A 2025 trial found ketamine plus naltrexone showed no difference from ketamine alone for MDD comorbid with AUD, suggesting opioid receptor antagonism did not alter therapeutic effects 9

Critical distinction: The naltrexone-bupropion combination's antidepressant effects likely derive primarily from bupropion, not naltrexone 6, 10

Anxiety Disorders

No direct evidence supports naltrexone for primary anxiety disorders.

• Guidelines note that anxiety, depression, bipolar disorder, and PTSD are more common in substance use disorder patients but do not recommend naltrexone for these conditions 11

• The 2016 obesity guidelines found maximal-dose phentermine/topiramate ER (not naltrexone) should be used with caution in anxiety disorders 10

Safety Considerations in Psychiatric Populations

Hepatotoxicity Risk

• Naltrexone causes hepatocellular injury at supratherapeutic doses 11
• Monitor liver function tests at baseline and every 3-6 months 11
• Not recommended in alcoholic liver disease due to hepatotoxicity risk 12

Psychiatric Monitoring

• FDA drug label notes depression, suicidal ideation, and suicide attempts have been reported in alcoholism treatment, though no causal relationship established 1
• Depression rates in naltrexone trials: 0-15% (naltrexone) vs 0-17% (placebo) 1
• Suicide attempt/ideation: 0-1% (naltrexone) vs 0-3% (placebo) 1

Contraindications

• Cannot be used with opioid therapy (blocks pain relief and precipitates withdrawal) 11, 6
• Must discontinue before procedures requiring opioids 6

Clinical Algorithm

When considering naltrexone for co-occurring psychiatric conditions:

1. First-line use: Only when substance use disorder (alcohol or opioid) is the primary diagnosis with psychiatric comorbidity 11, 13, 12

2. Consider off-label for BPD if:

   • Self-injurious behavior or dissociative symptoms are prominent 2, 4
   • Patient has adequate therapeutic support to manage reduced dissociation 3
   • Start low (2-6 mg/day) and titrate based on response 3
   • Higher doses (50-100 mg/day) may be more effective but require closer monitoring 2

3. Consider for PTSD only if:

   • Comorbid alcohol use disorder is present 5
   • Combine with evidence-based PTSD therapy 5

4. Do not use as monotherapy for:

   • Primary depression (insufficient evidence) 7, 9
   • Primary anxiety disorders (no evidence) 10
   • Primary PTSD without substance use disorder 5

5. Monitoring requirements:

   • Baseline and q3-6 month liver function tests 11
   • Screen for suicidal ideation (standard practice, not naltrexone-specific) 1
   • Assess for opioid use before each dose 11

The bottom line: Naltrexone's psychiatric benefits are largely confined to substance use disorders with psychiatric comorbidity, with emerging evidence for BPD-specific symptoms. It should not replace evidence-based treatments for primary psychiatric conditions 11, 14.